RVL Pharmaceuticals plc

2023 Q3 Form 10-Q Financial Statement

#000155837023014733 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.16M
YoY Change -32.87%
Cash & Equivalents $19.20M
Short-Term Investments
Other Short-Term Assets $3.305M
YoY Change -64.41%
Inventory $1.356M
Prepaid Expenses
Receivables $1.003M
Other Receivables $929.0K
Total Short-Term Assets $25.75M
YoY Change -35.92%
LONG-TERM ASSETS
Property, Plant & Equipment $3.805M
YoY Change 140.21%
Goodwill $55.85M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $59.65M
YoY Change -29.52%
TOTAL ASSETS
Total Short-Term Assets $25.75M
Total Long-Term Assets $59.65M
Total Assets $85.40M
YoY Change -31.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.530M
YoY Change -53.47%
Accrued Expenses $7.857M
YoY Change -34.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $57.75M
YoY Change 9413.67%
Total Short-Term Liabilities $68.39M
YoY Change 268.59%
LONG-TERM LIABILITIES
Long-Term Debt $63.60M
YoY Change 15.63%
Other Long-Term Liabilities $649.0K
YoY Change -86.16%
Total Long-Term Liabilities $63.60M
YoY Change 15.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.39M
Total Long-Term Liabilities $63.60M
Total Liabilities $69.08M
YoY Change 4.16%
SHAREHOLDERS EQUITY
Retained Earnings -$604.7M
YoY Change 12.71%
Common Stock $994.0K
YoY Change 18.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.33M
YoY Change
Total Liabilities & Shareholders Equity $85.40M
YoY Change -31.58%

Cashflow Statement

Concept 2023 Q3 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99161375
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99392165
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants http://www.rvlpharmaceuticals.com/20230630#FairValueAdjustmentOfDebt
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001739426
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38709
dei Entity Registrant Name
EntityRegistrantName
RVL Pharmaceuticals plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Address Address Line1
EntityAddressAddressLine1
400 Crossing Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
Bridgewater
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08807
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
809-1300
dei Security12b Title
Security12bTitle
Ordinary shares, $0.01 nominal value per share
dei Trading Symbol
TradingSymbol
RVLP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
99535197
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19159000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44543000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1932000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3031000
CY2023Q2 us-gaap Inventory Net
InventoryNet
1356000
CY2022Q4 us-gaap Inventory Net
InventoryNet
784000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3305000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8617000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
25752000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
56975000
CY2023Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3440000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1276000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
512000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13900000
CY2023Q2 us-gaap Goodwill
Goodwill
55847000
CY2022Q4 us-gaap Goodwill
Goodwill
55847000
CY2023Q2 us-gaap Assets
Assets
85404000
CY2022Q4 us-gaap Assets
Assets
128510000
CY2023Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2530000
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2407000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7857000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15395000
CY2023Q2 rvlp Long Term Debt Current Fair Value
LongTermDebtCurrentFairValue
57300000
CY2023Q2 rvlp Long Term Debt Current Net
LongTermDebtCurrentNet
70666000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
57748000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1432000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
10000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
10000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435000
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
50000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
44000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
68392000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19723000
CY2023Q2 us-gaap Fair Value Option Aggregate Differences Long Term Debt Instruments
FairValueOptionAggregateDifferencesLongTermDebtInstruments
75000000
CY2022Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
55500000
CY2023Q2 rvlp Warrant Liability
WarrantLiability
469000
CY2022Q4 rvlp Warrant Liability
WarrantLiability
1951000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
12000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
180000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94000
CY2022Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
70000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
25000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
61000
CY2023Q2 us-gaap Liabilities
Liabilities
69078000
CY2022Q4 us-gaap Liabilities
Liabilities
77417000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99392165
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
99161375
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
994000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
992000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 rvlp Common Stock Other Par Or Stated Value Per Share
CommonStockOtherParOrStatedValuePerShare
1.00
CY2022Q4 rvlp Common Stock Other Par Or Stated Value Per Share
CommonStockOtherParOrStatedValuePerShare
1.00
CY2023Q2 rvlp Common Stock Other Shares Authorized
CommonStockOtherSharesAuthorized
25000
CY2022Q4 rvlp Common Stock Other Shares Authorized
CommonStockOtherSharesAuthorized
25000
CY2023Q2 rvlp Common Stock Other Shares Issued
CommonStockOtherSharesIssued
0
CY2022Q4 rvlp Common Stock Other Shares Issued
CommonStockOtherSharesIssued
0
CY2023Q2 us-gaap Common Stock Other Value Outstanding
CommonStockOtherValueOutstanding
0
CY2022Q4 us-gaap Common Stock Other Value Outstanding
CommonStockOtherValueOutstanding
0
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
620055000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
619323000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-604723000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-569222000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16326000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
51093000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85404000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128510000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8258000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8448000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17090000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29892000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1946000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2227000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4245000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4371000
CY2023Q2 us-gaap Gross Profit
GrossProfit
6312000
CY2022Q2 us-gaap Gross Profit
GrossProfit
6221000
us-gaap Gross Profit
GrossProfit
12845000
us-gaap Gross Profit
GrossProfit
25521000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13886000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20169000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30084000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44003000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
547000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1176000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1173000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2038000
CY2023Q2 rvlp Impairment Of Intangible Assets Discontinued Operations
ImpairmentOfIntangibleAssetsDiscontinuedOperations
13900000
rvlp Impairment Of Intangible Assets Discontinued Operations
ImpairmentOfIntangibleAssetsDiscontinuedOperations
13900000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
28333000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
21345000
us-gaap Operating Expenses
OperatingExpenses
45157000
us-gaap Operating Expenses
OperatingExpenses
46041000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22021000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15124000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32312000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20520000
CY2023Q2 us-gaap Interest Expense
InterestExpense
13000
CY2022Q2 us-gaap Interest Expense
InterestExpense
978000
us-gaap Interest Expense
InterestExpense
39000
us-gaap Interest Expense
InterestExpense
1963000
CY2023Q2 rvlp Fair Value Adjustment Of Debt
FairValueAdjustmentOfDebt
3144000
CY2022Q2 rvlp Fair Value Adjustment Of Debt
FairValueAdjustmentOfDebt
-740000
rvlp Fair Value Adjustment Of Debt
FairValueAdjustmentOfDebt
10493000
rvlp Fair Value Adjustment Of Debt
FairValueAdjustmentOfDebt
304000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-805000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3455000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1482000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1053000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
371000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
78000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5806000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5115000
CY2023Q2 rvlp Non Operating Income Expense And Interest Expense
NonOperatingIncomeExpenseAndInterestExpense
-1981000
CY2022Q2 rvlp Non Operating Income Expense And Interest Expense
NonOperatingIncomeExpenseAndInterestExpense
3295000
rvlp Non Operating Income Expense And Interest Expense
NonOperatingIncomeExpenseAndInterestExpense
-3244000
rvlp Non Operating Income Expense And Interest Expense
NonOperatingIncomeExpenseAndInterestExpense
1795000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24002000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11829000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35556000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18725000
CY2023Q2 us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
-113000
CY2022Q2 us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
277000
us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
-55000
us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
202000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23889000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12106000
us-gaap Net Income Loss
NetIncomeLoss
-35501000
us-gaap Net Income Loss
NetIncomeLoss
-18927000
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
-1700000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23889000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12106000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35501000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20627000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99370291
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99370291
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83580906
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83580906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99345933
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99345933
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83535655
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83535655
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
76733000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1328000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-6821000
CY2022Q1 rvlp Additional Paid In Capital Income Tax Deficiency From Share Based Compensation Adjustment
AdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensationAdjustment
57000
CY2022Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
-1700000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
69483000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1208000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12106000
CY2022Q2 rvlp Additional Paid In Capital Income Tax Deficiency From Share Based Compensation Adjustment
AdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensationAdjustment
74000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
58511000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
51093000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
591000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11612000
CY2023Q1 rvlp Additional Paid In Capital Income Tax Deficiency From Share Based Compensation Adjustment
AdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensationAdjustment
72000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
40000000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
232000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-23889000
CY2023Q2 rvlp Additional Paid In Capital Income Tax Deficiency From Share Based Compensation Adjustment
AdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensationAdjustment
17000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16326000
us-gaap Profit Loss
ProfitLoss
-35501000
us-gaap Profit Loss
ProfitLoss
-18927000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180000
us-gaap Share Based Compensation
ShareBasedCompensation
731000
us-gaap Share Based Compensation
ShareBasedCompensation
2418000
rvlp Change In Fair Value Of Debt
ChangeInFairValueOfDebt
6134000
rvlp Change In Fair Value Of Debt
ChangeInFairValueOfDebt
-2600000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1482000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1053000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
13900000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-37000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
23000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
166000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
94000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1935000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1099000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-300000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
572000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-310000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5313000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3614000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
124000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1659000
rvlp Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
-7610000
rvlp Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
-1151000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17880000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11280000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
166000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
94000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2350000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67000
rvlp Consolidated Finance Lease Principal Payments
ConsolidatedFinanceLeasePrincipalPayments
5000
rvlp Consolidated Finance Lease Principal Payments
ConsolidatedFinanceLeasePrincipalPayments
4000
rvlp Repayment Of Insurance Financing Loan
RepaymentOfInsuranceFinancingLoan
984000
rvlp Repayment Of Insurance Financing Loan
RepaymentOfInsuranceFinancingLoan
1802000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
89000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
131000
rvlp Proceeds From Purchases Of Stock Under Employee Stock Purchase Plan
ProceedsFromPurchasesOfStockUnderEmployeeStockPurchasePlan
92000
rvlp Proceeds From Purchases Of Stock Under Employee Stock Purchase Plan
ProceedsFromPurchasesOfStockUnderEmployeeStockPurchasePlan
119000
us-gaap Repayments Of Debt
RepaymentsOfDebt
4334000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5320000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1818000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-25384000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13031000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44543000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40444000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19159000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27413000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. Organization and Nature of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RVL Pharmaceuticals plc, an Irish public limited company, together with its subsidiaries (collectively, the “Company”), is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In July 2020, the Company received regulatory approval from the FDA for RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Upneeq was commercially launched in September 2020 to a limited number of eye care professionals with commercial operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties. In February 2022, Upneeq was commercially expanded into the medical aesthetics market in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August 27, 2021, the Company closed the divestiture of its portfolio of branded and non-promoted products and its Marietta, Georgia, manufacturing facility (the “Legacy Business”) to certain affiliates of Alora Pharmaceuticals (“Alora”). Pursuant to the divestiture, the Company retained the rights to Upneeq and to arbaclofen ER tablets which had been under development for the treatment of spasticity in multiple sclerosis for which the Company had completed Phase III clinical trials and for which the Company has been exploring opportunities to divest, out-license or otherwise partner with a third party to monetize its net investment (see Note 15).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s commercial operations are conducted by its wholly-owned subsidiaries, RVL Pharmaceuticals, Inc. (“RVL Pharmaceuticals”) and RVL Pharmacy, LLC, (“RVL Pharmacy”). RVL Pharmacy conducts pharmacy operations dedicated to the processing and fulfillment of prescriptions for Upneeq. </p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported throughout the financial statements. Actual results could differ materially from those estimates. </p>
us-gaap Interest Paid Net
InterestPaidNet
6697000
us-gaap Interest Paid Net
InterestPaidNet
2931000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
75000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
142000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
5100000
CY2023Q2 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
800000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19200000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-604700000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
70700000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
35500000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
18900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11300000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8258000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8448000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17090000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29892000
CY2023Q2 rvlp Revenue From Contract With Customer Excluding Assessed Tax Before Adjustments
RevenueFromContractWithCustomerExcludingAssessedTaxBeforeAdjustments
8469000
CY2022Q2 rvlp Revenue From Contract With Customer Excluding Assessed Tax Before Adjustments
RevenueFromContractWithCustomerExcludingAssessedTaxBeforeAdjustments
8538000
rvlp Revenue From Contract With Customer Excluding Assessed Tax Before Adjustments
RevenueFromContractWithCustomerExcludingAssessedTaxBeforeAdjustments
17657000
rvlp Revenue From Contract With Customer Excluding Assessed Tax Before Adjustments
RevenueFromContractWithCustomerExcludingAssessedTaxBeforeAdjustments
14565000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1100000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1003000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
947000
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
929000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2084000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1932000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3031000
CY2023Q2 rvlp Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
3391000
CY2022Q4 rvlp Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5894000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2783000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3908000
CY2022Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
2300000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
542000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1144000
CY2023Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
1051000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1923000
CY2023Q2 rvlp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
90000
CY2022Q4 rvlp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
226000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7857000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15395000
CY2023Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
57748000
CY2022Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
56932000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
57748000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1432000
CY2022Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
55500000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
448000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
14133000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14133000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
42400000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
71114000
CY2023Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
7515000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
63599000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
232000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1209000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
731000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2418000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
1700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24002000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11829000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35556000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18725000
CY2023Q2 us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
-113000
CY2022Q2 us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
277000
us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
-55000
us-gaap Other Income Tax Expense Benefit Continuing Operations
OtherIncomeTaxExpenseBenefitContinuingOperations
202000
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0047
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0234
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0015
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0108
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
19200000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
44500000

Files In Submission

Name View Source Status
rvlp-20230630x10q_htm.xml Edgar Link completed
0001558370-23-014733-index-headers.html Edgar Link pending
0001558370-23-014733-index.html Edgar Link pending
0001558370-23-014733.txt Edgar Link pending
0001558370-23-014733-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvlp-20230630.xsd Edgar Link pending
rvlp-20230630x10q.htm Edgar Link pending
rvlp-20230630xex10d1.htm Edgar Link pending
rvlp-20230630xex31d1.htm Edgar Link pending
rvlp-20230630xex32d1.htm Edgar Link pending
Show.js Edgar Link pending
rvlp-20230630_cal.xml Edgar Link unprocessable
rvlp-20230630_def.xml Edgar Link unprocessable
rvlp-20230630_lab.xml Edgar Link unprocessable
rvlp-20230630_pre.xml Edgar Link unprocessable